BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
Category: #health  | By Nikita Chaurasia  | Date: 2019-12-31 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging artificial intelligence approaches to advance the next wave of medicines in immuno-oncology and neuroscience, has reportedly announced the initiation of its SERENITY program, two Phase 3 studies of BXCL501 for treating agitation in patients who are suffering from bipolar disorder and Schizophrenia.

According to Vimal Mehta, CEO of BioXcel, the beginning of the SERENITY clinical trials represented a crucial next step in the company’s aim to offer effective and safe therapy to millions of people who are suffer from agitation related to schizophrenia and bipolar disorder.

Mehta claims that managing agitation in patients suffering from neuropsychiatric disorders is a key challenge for both caregivers and physicians. Meanwhile, sources suggest that this treatment would provide calming with excessive sedation while protecting the caregiver-patient relationship.

For the record, the SERENITY studies are double-blinded, randomized, placebo-controlled, adaptive trials of up to 750 patients ranging from 18 to 75 years of age. The primary endpoint of these trials is reduced acute agitation measured by the Positive and Negative Syndrome Scale, analyzing the Excited Component (PEC) variation from baseline compared to placebo.

A key secondary endpoint comprises ascertaining the quickest time where an agitation effect is apparent as calculated by the variation from baseline in PEC score.

It is estimated that around 19 million people are at risk of agitation and 8.3 million people in the United States suffer from agitation every year, costing approx. $40 billion annually in treatment-related expenses.

As a potential treatment, BXCL501 is a first-in-class, trademarked sublingual thin film of selective alpha-2a receptor dexmedetomidine agonist for treating acute agitation. It is projected that topline data from these clinical trials are expected in mid-2020. Meanwhile, following this announcement, shares of BioXcel were reported up 9% premarket.
 

Source Link - https://www.bioxceltherapeutics.com/news-media/press-releases/detail/107/bioxcel-therapeutics-announces-initiation-of-pivotal-phase

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Samsung kickstarts chip production with 3nm process technology

Samsung kickstarts chip production with 3nm process technology

By Nikita Chaurasia

Samsung Electronics Co Ltd has reportedly declared that it has begun the mass production of chips using advanced 3-nanometre technology. The company is the first in the entire world to do so and is actively looking for new clients to contest with Tai...

Progcap nabs $40Mn in funding round for expansion & product development

Progcap nabs $40Mn in funding round for expansion & product development

By Nikita Chaurasia

Progcap, a pioneer in the field of corporate-driven financing solutions for small and medium-sized businesses (SMBs), has secured $40 million in private equity capital at $600 million valuation. The raised capital forms a part of the Series C exte...

Microsoft solidifies Qatar investment; Unveils new high-tech office

Microsoft solidifies Qatar investment; Unveils new high-tech office

By Nikita Chaurasia

Microsoft, the global tech behemoth, has recently stated that it is expanding its operation in Qatar by unveiling a new Lusail City unit, the firm’s largest and fourth in the country. This new facility forms part of a substantial investment tha...